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Background: Accurate diagnosis of heparin-induced thrombocytopenia (HIT) is essential but remains
challenging. We have previously demonstrated, in a retrospective study, the usefulness of the combination
of the 4Ts score, AcuStar HIT and heparin-induced multiple electrode aggregometry (HIMEA) with opti-
mized thresholds.
Objectives:We aimed at exploring prospectively the performances of our optimized diagnostic algorithm on
suspected HIT patients. The secondary objective is to evaluate performances of AcuStar HIT-Ab (PF4-H) in
comparison with the clinical outcome.
Methods: 116 inpatients with clinically suspected immune HIT were included. Our optimized diagnostic
algorithmwas applied to each patient. Sensitivity, speciﬁcity, negative predictive value (NPV), positive pre-
dictive value (PPV) of the overall diagnostic strategy as well as AcuStar HIT-Ab (at manufacturer’s thresh-
olds and at our thresholds) were calculated using clinical diagnosis as the reference.
Results: Among 116 patients, 2 patients had clinically-diagnosed HIT. These 2 patients were positive on
AcuStar HIT-Ab, AcuStar HIT-IgG and HIMEA. Using our optimized algorithm, all patients were correctly di-
agnosed. AcuStar HIT-Ab at our cut-off (N9.41 U/mL) and at manufacturer’s cut-off (N1.00 U/mL) showed
both a sensitivity of 100.0% and a speciﬁcity of 99.1% and 90.4%, respectively.
Conclusion: The combination of the 4Ts score, the HemosIL® AcuStar HIT and HIMEAwith optimized thresh-
olds may be useful for the rapid and accurate exclusion of the diagnosis of immune HIT.© 2014 Elsevier Ltd. All rights reserved.Introduction
Immune heparin-induced thrombocytopenia (HIT) is a severe
immunological adverse event of heparin therapy [1,2]. Early diagno-
sis is essential and both misdiagnosis and erroneous diagnosis
should be avoided [3]. Indeed, a misdiagnosis may expose the pa-
tient to life-threatening thrombosis. Delays in the starting of treat-
ment are associated with an initial 5%-10% daily risk of thrombosis,
amputation, organ dysfunction or death [1]. An overdiagnosis
may also lead to a discontinuation of the heparin treatment and a
substitution by another more expensive anticoagulant which could
be associated with an increased risk of bleeding without effective
antidote [3,4]. The current diagnostic relies on the use of a clinical
scoring algorithm (“4Ts score”) together with immunologicalartment of Pharmacy, Rue de
99 626462 (mobile); fax: +32
t).
ghts reserved.
d exclusion of the diagnosis o
.doi.org/10.1016/j.thromres.2and functional assays (i.e. platelet activation assays) [1,2]. This com-
bination improves HIT diagnosis compared to its components con-
sidered independently [5]. However, the scoring system has to be
used carefully and may require some extensive documentation of
the patient medical history [6]. Immunoassays are sensitive but
poorly speciﬁc. The HemosIL® AcuStar HIT-IgG (PF4-H) and AcuStar
HIT-Ab (PF4-H), two immunological assays, and the heparin-
induced multiple electrode aggregometry (HIMEA), a functional
assay, were recently proposed as new rapid methods for the diagno-
sis of HIT [7–9].
Previously, we performed a retrospective study on 106 patients with
suspected HIT. We showed that a diagnostic algorithm based on 4Ts
score, AcuStar HIT and HIMEA with optimized thresholds showed
good performances for the rapid and accurate diagnosis of immune
HIT (PPV: 88.9 % (95% CI: 51.7%-98.2%), NPV: 100.0 % (95% CI: 96.1%-
100.0%)) [10].
In the present study, we explored prospectively the performances of
our optimized diagnostic algorithm on HIT suspected patients in our
academic tertiary hospital. Secondly, we evaluated performances of
AcuStar HIT-Ab (PF4-H) in comparison with the clinical outcome.f immune HIT by AcuStar HIT and heparin-induced multiple electrode
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Patients
One hundred and sixteen inpatients (76 men and 40 women; 49
medical and 67 were surgical patients) suspected of developing HIT
from 1st November 2011 to 31th January 2013 at the CHU Dinant
Godinne - UCL Namur, Belgium, were included in the study, in accor-
dance with the local ethics committee.Healthy subjects
In order to perform HIMEA, whole blood samples from healthy
volunteers are needed. Blood was collected with a 20 gauge needle
via atraumatic antecubital venipuncture into polyethylene terephthal-
ate tubes Venosafe® (Terumo Europe, Leuven, Belgium) containing
25 μg/mL of recombinant hirudin (Verum Diagnostica GmbH, Munich,
Germany, 1:10 v/v). A discard tube was used to avoid tissue factor
contamination. Blood was obtained from two O Rh+/− blood group
donors. These donors did not take anymedicinewhich could potentially
affect their platelet function for 10 days before the blood sampling.
Platelet donorswere selected on the basis of a good reactivitywith plas-
ma of HIT patients. The platelet reactivity of the healthy donorswas also
assessed byHIMEAwith the following reagents: adenosine diphosphate
(ADP, ﬁnal concentration: 6.5 μM), collagen (type 1, ﬁnal concentration:
3.2 μg/mL), arachidonic acid (AA, ﬁnal concentration: 0.5 mM) or
thrombin receptor activating peptide (TRAP-6, ﬁnal concentration 32
μM) (Dynabyte, Munich, Germany). Each volunteer presented normal
aggregation.Fig. 1. Flow chart with results. Thresholds for AcuStar HIT-Ab, AcuStar HIT-IgG and HIMEA are, r
385 IU/mL UFH.
Please cite this article as: Minet V, et al, Rapid exclusion of the diagnosis o
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Routine laboratory diagnosis was performed on HIT patients
according to our optimized algorithm (Fig. 1) (except for AcuStar HIT-
Ab which was performed on each patient). This ﬂow chart is based
on (1) 4Ts score, (2) AcuStar HIT (PFA-H) (immunological assay), and
(3) HIMEA (functional assay).
4Ts score and clinical diagnosis
HIT was suspected because of a rapidly decreasing platelet count oc-
curring in hospitalised patients under heparin therapy. Subsequently,
the “4Ts score” was calculated (based on four criteria: the severity of
the thrombocytopenia and its timing, the occurrence of a thrombosis
and the exclusion of other causes of thrombocytopenia). Clinical data
were recorded in real time in the hospital medical database. Clinical
outcomes were retrospectively and independently conﬁrmed by two
investigators (VM and FM), not aware of the results of the laboratory
assays. Clinical diagnoses made by these 2 local investigators were
100% concordant among them and with conclusions of the medical
database. Several clinical criteria have to be fulﬁlled for the conﬁrmation
of clinical HIT diagnosis. Criteria from the ACCP (American College of
Chest Physicians) guidelines were used to make the clinical diagnosis
of HIT: (1) Thrombocytopenia, deﬁned as at least a 30% decline in the
platelet count, with a platelet count increase after heparin cessation;
(2) Timing of platelet count fall after the initiation of heparin occurring
between 4 and 14 days, or occurring within 24 to 48 hours (in case of
prior heparin exposure within 30 days); and (3) lack of other, predom-
inant causes of thrombocytopenia [11–13]. Other causes of thrombocy-
topenia analysed in this study were: neoplasia, current pregnancy orespectively, 9.41 U/mL, 2.89 U/mL and 276 U/mL at 1 IU/mL UFH and a reduction N 80% at
f immune HIT by AcuStar HIT and heparin-induced multiple electrode
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agulation, intra-aortic balloon pump counterpulsation, multitransfusion,
multi-trauma, shock syndrome and drug-induced thrombocytopenia
(quinolone, β-lactam, vancomycin, teicoplanin, rifampicin, isoniazid,
amphotericin, ﬂuconazole, chemotherapy, anti-GPIIb/IIIa; furosemide
and proton pump inhibitors). All these 3 clinical criteria have to be
fulﬁlled for the conﬁrmation of clinical HIT diagnosis. The following infor-
mation was taken into consideration: patient’s medical history, types
(fractionated vs. unfractionated) and doses of heparin administered,
thrombotic complications, alternative diagnoses, therapeutic attitude,
clinical and platelet count evolution, co-suspectedmedications, and phy-
sician’s diagnoses [10,13].
Laboratory testing
Bloodwas collectedwith a 20 gauge needle via atraumatic antecubital
venipuncture into polyethylene terephthalate tubes Venosafe® (Terumo
Europe, Leuven, Belgium) containing buffered sodium citrate (109 mM,
nine parts of blood to one part sodium citrate solution). Plasmas were
tested prospectively in real time.
Immunological assay: AcuStar HIT-IgG (PF4-H) and AcuStar HIT-Ab (PF4-H)
The HemosIL® AcuStar HIT-IgG (PF4-H) and HIT-Ab (PF4-H) (In-
strumentation Laboratory, Bedford, MA, USA) are two chemilumines-
cent two-step immunoassays detecting the presence of anti-PF4-
heparin antibodies. The ﬁrst one is speciﬁc for IgG, the second one is
polyspeciﬁc (IgG, IgA and IgM). These assays have been described by
Legnani et al. [7]. The immunological isotype mainly responsible for
HIT is IgG [14]. IgM and IgA only play a minor role but we cannot rule
out the possibility of these immunoglobulins to contribute to some
degree of thrombocytopenia [15]. Consequently, in our algorithm, we
decided to perform a ﬁrst screening with AcuStar HIT-Ab (PF4-H).
AcuStar HIT-IgG (PF4-H) is then applied in case of a positive result.
AcuStar HIT-Ab (PF4-H) was performed for each patient regardless the
4Ts score. AcuStar HIT-IgG (PF4-H) was carried out on patients accord-
ing to our ﬂow chart (Fig. 1).
The threshold recommended by the manufacturer is 1.00 U/mL.
We used the thresholds determined in our previous retrospective
study, i.e. 2.89 U/mL and 9.41 U/mL for AcuStar HIT-IgG (PF4-H) and
AcuStar HIT-Ab (PF4-H), respectively.
Functional assay: Heparin-induced multiple electrode aggregometry
(HIMEA)
Multiple electrode aggregometry (MEA) is a method for the assess-
ment of platelet function in whole blood (Multiplate® analyzer;
Dynabyte, Munich, Germany) [16]. MEA is based on the principle of im-
pedance aggregometry. Our protocol has already been described [10].
Each HIMEA assay is performed in real-time with the fresh blood of
one of the two determined healthy donors. Results are expressedTable 1
Comparison of HemosIL® AcuStar HIT-IgG (PF4-H), HIT-Ab (PF4-H) and optimized diagnostic
diagnosis available; n = 46: patients with medium-high pre-test probability; AU: arbitrary un
Clinical diagnosis
Negative Positive
AcuStar HIT-Ab (n = 116) Threshold: N1.00 U/mL Negative 103 0
Positive 11 2
AcuStar HIT-Ab (n = 116) Threshold: N9.41 U/mL Negative 113 0
Positive 1 2
AcuStar HIT-Ab (n = 46) Threshold: N1.00 U/mL Negative 40 0
Positive 4 2
AcuStar HIT-Ab (n = 46) Threshold: N9.41 U/mL Negative 44 0
Positive 0 2
Optimized diagnostic
algorithm (n = 116)
Thresholds: N3; N9.41 U/mL;
N 2.89 U/mL; N276 AU
Negative 114 0
Positive 0 2
Please cite this article as: Minet V, et al, Rapid exclusion of the diagnosis o
aggregometry, Thromb Res (2014), http://dx.doi.org/10.1016/j.thromres.2using the area under the aggregation curve (AUC) and the recording
time is 30 minutes. The result is considered to be positive when the
platelet aggregation occurred in the presence of low heparin concentra-
tion (1 IU/mLUFH) but is partially inhibited (reduction N 80%) by a high
concentration of heparin (385 IU/mL UFH). The threshold determined
in our retrospective study was 276 AU at 1 IU/mL UFH.
Data analysis
Data analysis was performed using Medcalc software (version
10.4.8) (MedCalc Software bvba, Ostend, Belgium). The sensitivity, the
speciﬁcity, the negative predictive value (NPV) and the positive predic-
tive value (PPV) of AcuStar HIT-Ab (PF4-H)were assessed using clinical
diagnosis as reference.
Results
Out of the 116 patients included in this study, two (1.7%) were con-
sidered to have developed HIT based on our clinical diagnosis. The ﬁrst
one experienced a pulmonary embolism and the other one died during
his hospitalisation following coronary thrombosis. Complete compres-
sion ultrasonography and multidetector spiral computed tomography
were performed for suspected thrombosis.
Assessment of our optimized diagnostic algorithm (Fig. 1)
Among 116 patients included in this study, 70 patients (60.3 %), 44
patients (37.9%) and 2 patients (1.7%) presented a low (≤3), medium
(4–6) and high (7–8) 4Ts score, respectively. No patient with a low
PTP was diagnosed as having HIT.
Among 46 patients with a medium-high PTP score, HIT was exclud-
ed in 44 patients with AcuStar HIT-Ab (PF4-H) (threshold: 9.41 U/mL)
(Fig. 1). The NPV and PPV of AcuStar HIT-Ab (PF4-H) was 100.0% (95%
CI: 91.9%-100.0%) and 100.0% (95% CI: 19.3%-100.0%), respectively
(Table 1). The 2 patients AcuStar HIT-Ab (PF4-H) positivewere also pos-
itive on AcuStar HIT-IgG (PF4-H) (threshold: 2.89 U/mL) and on HIMEA
(threshold: 276 AU at 1 IU of UFH). These two patients had clinically
conﬁrmedHIT. The sensitivity, speciﬁcity, PPV andNPV of this combina-
tion using our thresholds, for the 116 patients were 100.0 % (95% CI:
16.6%-100.0%), 100.0% (95% CI: 96.8%-100.0%), 100.0% (95% CI: 96.8%-
100.0%) and 100.0% (95% CI: 16.6%-100.0%), respectively. (See Table 2.)
Comparison of performances of AcuStar HIT-Ab (PF4-H) at our threshold
(9.41 U/mL) and at manufacturer’s threshold (1.00 U/mL) (Table 1)
AcuStar HIT-Ab (PF4-H)was performed on each patient of the study
regardless of the 4Ts score. For all patients (n= 116) at manufacturer’s
threshold, there were 11 false positives against 1 false positive at our
threshold. The false positive result on AcuStar HIT-Ab (9.96 U/mL)algorithm with the clinical diagnosis (n = 116: all patients suspected of HIT with clinical
it, NPV: negative predictive value, PPV: positive predictive value).
Sensitivity % (95%CI) Speciﬁcity % (95%CI) NPV % (95%CI) PPV % (95%CI)
100.0 (19.3-100.0) 90.4 (83.4-95.1) 100.0 (96.5-100.0) 15.4 (2.4-45.5)
100.0 (19.3-100,0) 99.1 (95.2-99.9) 100.0 (96.8-100.0) 66.7 (11.6-94.5)
100.0 (19.3-100.0) 90.9 (78.3-97.4) 100.0 (91.1-100.0) 33.3 (5.3-77.3)
100.0 (19.3-100.0) 100.0 (91.9-100.0) 100.0 (91.9-100.0) 100.0 (19.3-100.0)
100.0 (16.6-100.0) 100.0 (96.8-100.0) 100.0 (96.8-100.0) 100.0 (16.6-100.0)
f immune HIT by AcuStar HIT and heparin-induced multiple electrode
014.01.014
Ta
bl
e
2
Cl
in
ic
al
an
d
la
bo
ra
to
ry
da
ta
fo
r
th
e
2
pa
ti
en
ts
w
it
h
a
po
si
ti
ve
di
ag
no
si
s
of
H
IT
.
La
bo
ra
to
ry
as
sa
ys
Cl
in
ic
al
da
ta
A
cu
St
ar
H
IM
EA
4T
s
Cl
in
ic
al
ev
ol
ut
io
n
fr
om
th
e
H
IT
su
sp
ic
io
n
to
th
e
di
sc
ha
rg
e
fr
om
ho
sp
it
al
H
IT
A
b
(U
/m
L)
Ig
G
(U
/m
L)
1
IU
/m
L
(A
U
C)
Th
ro
m
bo
cy
to
pe
ni
a
Ti
m
in
g
of
th
ro
m
bo
cy
to
pe
ni
a
Th
ro
m
bo
si
s
or
ot
he
r
se
qu
el
ae
O
th
er
ca
us
es
fo
r
th
ro
m
bo
cy
to
pe
ni
a
4T
s
sc
or
e
St
op
he
pa
ri
n
Pl
at
el
et
co
un
t
in
cr
ea
se
Cl
in
ic
al
di
ag
no
si
s
Pa
ti
en
t
1
11
.1
1
5.
03
44
8
Pl
at
el
et
co
un
t
fa
ll
N
50
%
an
d
pl
at
el
et
na
di
r
≥
20
(2
po
in
ts
)
Cl
ea
r
on
se
ta
t
da
y
7,
no
pr
io
r
he
pa
ri
n
ex
po
su
re
w
it
hi
n
30
da
ys
(2
po
in
ts
)
Lu
ng
em
bo
lis
m
an
d
de
ep
ve
no
us
th
ro
m
bo
si
s
(2
po
in
ts
)
Po
ss
ib
le
(1
po
in
t)
(T
az
oc
in
®
)
7
+
+
+
Pa
ti
en
t
2
47
.3
0
46
.8
1
66
4
Pl
at
el
et
co
un
t
fa
ll
N
50
%
an
d
pl
at
el
et
na
di
r
≥
20
(2
po
in
ts
)
Cl
ea
r
on
se
ta
t
da
y
7,
no
pr
io
r
he
pa
ri
n
ex
po
su
re
w
it
hi
n
30
da
ys
(2
po
in
ts
)
Co
ro
na
ry
th
ro
m
bo
si
s
(2
po
in
ts
)
Po
ss
ib
le
(1
po
in
t)
(A
ug
m
en
ti
n®
,N
ex
ia
m
®
,d
ia
ly
si
s)
7
+
N
D
(d
ea
th
)
+
4 V. Minet et al. / Thrombosis Research xxx (2014) xxx–xxx
Please cite this article as: Minet V, et al, Rapid exclusion of the diagnosis o
aggregometry, Thromb Res (2014), http://dx.doi.org/10.1016/j.thromres.2was slightly above our threshold (9.41 U/mL). Speciﬁcity was signiﬁ-
cantly higher at our threshold, i.e. 99.1% (95% CI: 95.2%-99.9%) than at
manufacturer’s threshold, i.e. 90.4% (95% CI: 83.4%-95.1%). Among pa-
tients with a medium-high pre-test probability (n= 46), our threshold
presented no false positives against the 4 false positive at manufac-
turer’s threshold. Using our threshold, the speciﬁcity reached 100.0 %
(95% CI: 91.9%-100.0%), and it was 90.9% (95% CI: 78.3%-97.4%) with
the manufacturer’s threshold.
Discussion
We performed the present study with the aim of assessing prospec-
tively our immune HIT diagnostic algorithmwith optimized thresholds
(Fig. 1). Among 116 inpatients suspected of HIT, every patient was
correctly diagnosed using our ﬂow chart. Speciﬁcity was higher at our
threshold (99.1% (95% CI: 95.2%-99.9%)) than at manufacturer’s thresh-
old (i.e. 90.4% (95% CI: 83.4%-95.1%)).
Applying our diagnostic algorithm, heparin therapy should be
continued and no subsequent laboratory assay should be performed in
patients with a 4Ts score ≤ 3 [1]. In this study, no patient with a low
probability 4Ts score (≤3) (n = 70) was diagnosed as having HIT. It
conﬁrms the effectiveness of the 4Ts score to limit additional biological
assays. Cuker et al. also concluded in a systematic review and meta-
analysis that 4Ts score of patients with suspected HIT may reduce
overtesting and overdiagnosis of suspected HIT patients and that a
low probability 4Ts score was a robust tool to exclude HIT [17].
The HemosIL® AcuStar HIT-IgG (PF4-H) and AcuStar HIT-Ab (PF4-H)
were proposed as chemiluminescent immunoassays. AcuStar can be
run for single sample testing and it presents shorter running-time
(30 minutes) than other commercially available immunologic assays
(2–3 hours).
In our previous retrospective study, we demonstrated that the use
of optimized thresholds markedly improved the speciﬁcity of AcuStar
HIT-Ab (PF4-H) [10]. A recent study concluded that the diagnostic accu-
racy of the anti-PF4/heparin ELISA can be optimized by using a higher
cut-off [18]. Using optimized thresholds in our algorithm should reduce
overdiagnosis of HIT and the need to perform additional HIMEA. Actual-
ly, the manufacturers provided thresholds following a study on healthy
subjects and not on a HIT suspected patient’s population.
The HIMEA is a rapid functional assay. It can be performed within
15 minutes and does not require any preparation of patient’s sample.
However, the immediate availability of a healthy compatible blood
group donor is required.
Our study suffers from some limitations. Firstly, it is a single-centre
study, and therefore it does not allow inter-laboratory comparisons.
Secondly, because of the intermediate size of our cohort the power
of this study is limited. In a recent study, Althaus et al. deﬁned lower
cut-offs than in our study. Our cut-offs should be further validated or
adjusted using larger sample size in a multicentre study to provide a
sufﬁciently high NPV beside their excellent PPV [19]. However, it should
be noted that due to the inter-instrument variation a ﬁxedOD threshold
of an assay depends of the instrument. Therefore, each laboratory
should determine their cut-offs with a cohort of HIT suspected patients.
Thirdly, our protocolmay differ fromother studies since no guideline on
standardized HIMEA procedure is available [8,20]. The threshold
depends on variables including volume of whole blood of the healthy
subject, volume of sample of patients, volume and concentration of
heparin, duration of the measurement and the platelet reactivity of
the healthy donors. Finally, to ascertain the diagnosis of HIT as recom-
mended by the consensus committee of the ISTH working group [21],
it is necessary to perform a washed platelet activation assay. 14C-
Serotonin Release Assay (SRA) is still considered as one of the reference
method but it has not been performed in this study. This assay is indeed
not available in most routine hospital laboratories because of its well-
known limitations (time-consuming, technically demanding and
requires the use of radioactive material).f immune HIT by AcuStar HIT and heparin-induced multiple electrode
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5V. Minet et al. / Thrombosis Research xxx (2014) xxx–xxxConclusion
In this study, we demonstrated that the combination of the 4Ts
score, theHemosIL®AcuStar HIT andHIMEAwith optimized thresholds
may be useful for the rapid and accurate exclusion of the diagnosis
of immune HIT among the 116 included patients. A large multicentre
prospective study is needed to further validate our algorithm.
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